MedTrace Logo

Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients

NCT03237728 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-01-22

No results posted yet for this study

Summary

Phase I study of multiple-dose Kukoamine B Mesilate in Sepsis Patients

Conditions

Interventions

DRUG

0.06mg/kg,KB

0.06mg/kg,Q8h,Day1-Day7

DRUG

0.12mg/kg,KB

0.12mg/kg,Q8h,Day1-Day7

DRUG

0.24mg/,KB

0.24mg/kg,Q8h,Day1-Day7

DRUG

Placebos

Placebos,Q8h,Day1-Day7

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Tianjin Chasesun Pharmaceutical Co., LTD

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-28
Primary Completion
2019-09-25
Completion
2019-09-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03237728 on ClinicalTrials.gov